ClinicalTrials.gg
Active, not recruitingNCT06185764GalileoUpdated Aug 20, 2026

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

A Phase 1/2 interventional study of VX-670 and Placebo in Myotonic Dystrophy Type 1 (DM1), sponsored by Vertex Pharmaceuticals Incorporated. Active, not recruiting at 26 sites in 10 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 43 studies in Myotonic Dystrophy with a site in United States — 23 open to participants now, 27 under way, 4 of them phase 3. Myotonic Dystrophy · United States.

Enrollment
11th of 22
47 · median 46
Started
2024
with 2 others
Phase 1/2
7 of 43
2 open now
Primary completion
2027-02
later than 5 of 26 live
Registered
29th of 43
by date
Lead sponsor
2 of 43
Vertex Pharmaceuticals Incorporated

Among the 43 studies in Myotonic Dystrophy with a site in United States, this one is the 11th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 in phase 1/2, reaches primary completion later than 5 of the 26 other live ones, and was the 29th registered.

Myotonic Dystrophy

126 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

23 of the 43 studies in Myotonic Dystrophy with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Myotonic Dystrophy with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.

03

Conditions studied

  • Myotonic Dystrophy Type 1 (DM1)

Keywords

  • DM1
  • DM2
  • Myotonic Dystrophy 1
  • Myotonic Dystrophy 2
  • Myotonic Dystrophy Type 1 (DM1)
  • Myotonic Dystrophy
  • DM
  • Myotonia
  • Dystrophy Myotonic
  • Myotonic Disorders
  • Steinert Disease
  • Vertex
  • Entrada
  • VX-670
  • VX670
  • PMO
  • ASO
  • Myotonic Muscular Dystrophy
  • Muscular Disorders, Atrophic
  • Muscular Diseases
  • Musculoskeletal Diseases
  • Neuromuscular Diseases
  • Nervous System Diseases
  • Genetic Diseases, Inborn
  • Heredodegenerative Disorders, Nervous System
  • Neurodegenerative Diseases
  • Muscular Dystrophies
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

- Documented clinical diagnosis of DM1 with age of onset greater than (>) 1 year of age and documented positive genetic test for DM1 in the subject with cytosine thymine guanine (CTG) repeat of at least 100

Key Exclusion Criteria:

- History of any illness or any clinical condition as pre-specified in the protocol

Other protocol defined Inclusion/Exclusion criteria may apply.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Part A: Single Ascending Dose

    Participants will be randomized to receive a single dose of different dose levels of VX-670.

    Drug: VX-670

  • Placebo comparator
    Part A: Placebo

    Participants will be randomized to receive single dose of placebo matched to VX-670.

    Drug: Placebo

  • Experimental
    Part B: Single and Multiple Ascending Dose

    Participants will be randomized to receive single and multiple doses of different dose levels of VX-670. The dose levels will be determined based on the data from Part A.

    Drug: VX-670

  • Placebo comparator
    Part B: Placebo

    Participants will be randomized to receive single or multiple doses of placebo matched to VX-670.

    Drug: Placebo

Interventions

  • DrugVX-670

    Solution for intravenous administration.

  • DrugPlacebo

    Solution for intravenous administration.

06

What researchers measure

Primary outcomes

  1. Parts A and B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)

    Time frame: Part A: From Baseline up to Day 42; Part B: From Baseline and up to Day 168

Secondary outcomes

  1. Part A: Maximum Observed Concentration (Cmax) of VX-670 and its Active Component in Plasma

    Time frame: From Day 1 up to Day 42

  2. Part A: Area Under the Concentration Versus Time Curve (AUC) of VX-670 and its Active Component in Plasma

    Time frame: From Day 1 up to Day 42

  3. Part B: Maximum Observed Concentration (Cmax) of VX-670 and its Active Component in Plasma After Each Dose

    Time frame: From Day 1 up to Day 168

  4. Part B: Area Under the Concentration Versus Time Curve (AUC) of VX-670 and its Active Component in Plasma After Each Dose

    Time frame: From Day 1 up to Day 168

  5. Part B: Concentration of VX-670 and its Active Component in Muscle

    Time frame: Baseline, Day 15 and Day 120

  6. Part B: Change in Splicing Index in Muscle Biopsy

    Time frame: Baseline, Day 15 and Day 120

07

Study locations

26 sites
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Feb 2027, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2023
First posted
Dec 29, 2023
StartActual
Feb 20, 2024
Primary completionEst.
Feb 2, 2027
CompletionEst.
Feb 2, 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06185764
Responsible party
Sponsor
First posted
Dec 29, 2023
Start date
Feb 20, 2024
Primary completion
Feb 2, 2027 (estimated)
Completion
Feb 2, 2027 (estimated)
Last update
Aug 20, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion